Daiwa Securities Group Inc. - DAY ONE BIOPHARMACEUTICALS I ownership

DAY ONE BIOPHARMACEUTICALS I's ticker is DAWN and the CUSIP is 23954D109. A total of 129 filers reported holding DAY ONE BIOPHARMACEUTICALS I in Q3 2023. The put-call ratio across all filers is 2.14 and the average weighting 0.4%.

Quarter-by-quarter ownership
Daiwa Securities Group Inc. ownership history of DAY ONE BIOPHARMACEUTICALS I
ValueSharesWeighting
Q3 2023$40.0%2960.0%0.00%
Q2 2023$40.0%2960.0%0.00%
Q1 2023$4
-33.3%
2960.0%0.00%
Q4 2022$6
-99.8%
296
+63.5%
0.00%
Q3 2022$4,000
+33.3%
1810.0%0.00%
Q2 2022$3,000
+50.0%
1810.0%0.00%
Q1 2022$2,000
-33.3%
1810.0%0.00%
Q4 2021$3,0001810.00%
Other shareholders
DAY ONE BIOPHARMACEUTICALS I shareholders Q3 2023
NameSharesValueWeighting ↓
Canaan Partners XI LLC 2,548,403$54,841,63343.06%
PATHWAY CAPITAL MANAGEMENT, LP 995,686$21,427,16338.24%
Atlas Venture Life Science Advisors, LLC 7,568,317$162,870,18219.62%
RA Capital Management 7,040,622$151,514,1853.07%
COMMODORE CAPITAL LP 739,661$15,9182.40%
GREAT POINT PARTNERS LLC 544,451$11,716,5862.30%
Nicholas Investment Partners, LP 786,554$16,926,6421.48%
Boxer Capital, LLC 1,189,943$25,607,5731.35%
Parkman Healthcare Partners LLC 224,483$4,830,8741.29%
Cheyne Capital Management (UK) LLP 27,223$585,8391.02%
View complete list of DAY ONE BIOPHARMACEUTICALS I shareholders